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Abstract
 
We and others recently reported tumor necrosis factor (TNF) and apoptosis ligand–related leu-
kocyte-expressed ligand 1 (TALL-1) as a novel member of the TNF ligand family that is func-
tionally involved in B cell proliferation. Transgenic mice overexpressing TALL-1 have severe B
cell hyperplasia and lupus-like autoimmune disease. Here, we describe expression cloning of a
cell surface receptor for TALL-1 from a human Burkitt’s lymphoma RAJI cell library. The
cloned receptor is identical to the previously reported TNF receptor (TNFR) homologue trans-
membrane activator and calcium modulator and cyclophilin ligand (CAML) interactor (TACI).
Murine TACI was subsequently isolated from the mouse B lymphoma A20 cells. Human and
murine TACI share 54% identity overall. Human TACI exhibits high binding affinities to both
human and murine TALL-1. Soluble TACI extracellular domain protein specifically blocks
TALL-1–mediated B cell proliferation without affecting CD40- or lipopolysaccharide-mediated
B cell proliferation in vitro. In addition, when injected into mice, soluble TACI inhibits anti-
body production to both T cell–dependent and –independent antigens. By yeast two-hybrid
screening of a B cell library with TACI intracellular domain, we identified that, like many other
TNFR family members, TACI intracellular domain interacts with TNFR-associated factor
(TRAF)2, 5, and 6. Correspondingly, TACI activation in a B cell line results in nuclear factor
 
k
 
B and c-Jun NH
 
2
 
-terminal kinase activation. The identification and characterization of the re-
ceptor for TALL-1 provides useful information for the development of a treatment for B cell–
mediated autoimmune diseases such as systemic lupus erythematosus. 
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Introduction
 
The TNFR family includes, among others, TNFR1, TNFR2,
Fas, CD40, OX40, 4-1BB, death receptor (DR)3/Wsl-1,
DR4, DR5, another TNFR-associated factor (TRAF) re-
ceptor (ATAR), osteoprotegerin (OPG), and receptor acti-
 
vator of nuclear factor (NF)-
 
k
 
B (RANK [1–9]). These re-
ceptors share similar extracellular domain architecture of
multiple cysteine-rich repeats, each containing 
 
z
 
40 amino
acids with six cysteines (1). The extracellular domains are
usually preceded by hydrophobic signal peptides. Soluble
receptors could be generated by deleting the transmem-
brane and intracellular domains. The intracellular domains
lack enzymatic activities. The receptors may be divided
into two subgroups based on the presence (e.g., TNFR1,
Fas, DR3, DR4, DR5) or absence (e.g., TNFR2, CD40,
RANK) of death domains within their intracellular do-
mains (10). The receptors generally signal through direct
interaction with death domain proteins (e.g., TNFR-asso-
ciated death domain [TRADD], Fas-associated death do-
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main [FADD], receptor-interacting protein [RIP]) or
with TRAF proteins (e.g., TRAF2, TRAF3, TRAF5, and
TRAF6), triggering cellular signaling pathways leading to
apoptosis, NF-
 
k
 
B activation, and/or c-Jun NH
 
2
 
-terminal
kinase (JNK) activation (10).
We and others recently reported that TNF- and apopto-
sis ligand–related leukocyte expressed ligand 1 (TALL-1)/B
lymphocyte stimulator (BlyS)/B cell activating factor be-
longing to the TNF family (BAFF)/TNF homologue that
activates apoptosis, NF-
 
k
 
B, and JNK (THANK) is a novel
member of the TNF ligand family involved in B cell prolif-
eration (11–15). TALL-1 is a potent B cell costimulatory
factor, and acts by direct binding and by activating its cell
surface receptor on B cells. Transgenic mice overexpressing
TALL-1 have severe B cell hyperplasia and hypergamma-
globulinemia (11, 16). These mice also developed autoim-
mune lupus-like disease characterized by the presence of
autoantibodies and immune complex deposits in the kid-
ney (11, 16). 
Here, we report expression cloning of a TALL-1 recep-
tor from the human Burkitt’s lymphoma RAJI cell line.
The receptor is identical to transmembrane activator and
calcium modulator and cyclophilin ligand (CAML) interac-
tor (TACI), a previously reported TNFR homologue
identified through its interaction with CAML (17). Our
findings suggest the potential presence of another unique
subgroup within the TNFR family.
 
Materials and Methods
 
Reagents.
 
RAJI cells and A20 cells (American Type Culture
Collection) were maintained in high-glucose RPMI containing
10% FCS, 100 
 
m
 
g/ml penicillin G, and 100 
 
m
 
g/ml streptomycin.
A20 cDNA library was prepared using the Superscript Plasmid
System (GIBCO BRL). Human lymphocyte matchmaker cDNA
library was generated from mRNA of an EBV-transformed pe-
ripheral blood B cell population (CLONTECH Laboratories,
Inc.). Recombinant TALL-1 protein was generated as described
previously (11). TALL-1 Europium labeling was performed with
Wallac Delfia reagent according to the manufacturer’s sugges-
tions.   Fc-tagged TALL-1 protein was generated by the fusing
OPG signal peptide followed by human IgG-
 
g
 
1 Fc in frame to
the NH
 
2
 
-terminus of TALL-1 amino acid 128–285. The protein
was expressed in baculovirus and purified with protein A–seph-
arose column (5). Soluble TACI protein amino acids 1–165
followed by a His
 
6
 
-tag or human IgG-
 
g
 
1 Fc were expressed in
 
Escherichia coli
 
. After solubilization of the inclusion bodies, the re-
folded protein was purified by cation exchange chromatography.
 
Expression Cloning.
 
A RAJI cell expression library was gener-
ated by ligating RAJI cDNA into a mammalian expression vector
using the Superscript Plasmid System (GIBCO BRL) according
to the manufacturer’s suggestions. The library was arrayed into
segregated pools containing 
 
z
 
100 clones per pool, and the DNA
was purified from 1 ml overnight cultures of each pool grown.
Plasmid DNA from each culture was prepared using the Qiawell
96 Ultra Plasmid Kit (QIAGEN), following the manufacturer’s
instructions. Arrayed pools were individually transfected into 293
cells (American Type Culture Collection), then assayed for the
presence of Europium-labeled TALL-1 protein binding using a
Victor™ plate reader (Wallac, Inc.)
 
B Cell Proliferation Assay.
 
Purified (10
 
5
 
) B cells from C57BL/6
(B6) mice (11) were cultured in MEM
 
 
 
plus 10% heat-inactivated
FCS in triplicate in a 96-well flat-bottomed plate with 10 ng/ml
TALL-1 protein, 2 
 
m
 
g/ml goat F(ab
 
9
 
)
 
2
 
 anti–mouse IgM (Jackson
ImmunoResearch Laboratories), and an indicated amount of re-
combinant soluble TACI protein for a period of 4 d at 37
 
8
 
C, 5%
CO
 
2
 
. Proliferation was measured by the uptake of radioactive
[
 
3
 
H]thymidine in the last 18 h of pulse.
 
TACI Expression on PBMCs.
 
Human PBMCs from healthy
donors were isolated using Ficoll-paque density centrifugation.
Cells were washed and incubated with 1 
 
m
 
g/ml anti-CD3 anti-
body. Expression of TALL-1 receptor on activated CD4/CD8 T
cells was detected using Flag-tagged TALL-1 followed by bio-
tinylated anti-Flag antibody and streptavidin-PE. Biotinylated anti-
Flag antibody and streptavidin-PE reagents were used as controls
for nonspecific staining. FITC-conjugated anti-CD4 or anti-CD8
antibodies (BD PharMingen) were used to detect TALL-1 recep-
tor on specific cell types. Expression of cell surface molecules was
determined using CELLQuest™ software by FACS
 
®
 
 (Becton
Dickinson).
 
Induction and Detection of Anti-KLH and Anti-Pneumovax Anti-
bodies.
 
Mice (9–11-wk-old Balb/c females; Charles River Lab-
oratories) were immunized on day 0 subcutaneously with 100 
 
m
 
g
of KLH (Pierce Chemical Co.) in CFA or intraperitoneally with
115 
 
m
 
g of Pneumovax (Merck). Starting on day 0, mice received
7 daily intraperitoneal injections of 5 mg/kg of either soluble
TACI-Fc fusion protein or nonfused Fc as control, and were bled
on day 7. Anti-KLH and anti-Pneumovax IgG and IgM were
measured in serum by ELISA. In brief, for the measurement of
anti-KLH antibodies, plates were coated with KLH in PBS,
blocked, and added with test samples or dilutions of standard.
Captured anti-KLH IgGs or IgMs were revealed using anti-IgG
or anti-IgM biotinylated antibodies and neutravidin-conjugated
horseradish peroxidase, and were quantified by comparisons to
standards. For the measurement of anti-Pneumovax IgM, plates
were coated with Pneumovax using poly-
 
l
 
-lysine, blocked, and
added with dilutions of standard and test samples. Captured anti-
Pneumovax IgMs were revealed using an anti-IgM biotinylated
antibody and neutravidin-conjugated horseradish peroxidase.
Results were compared with the Student’s 
 
t
 
 test.
 
Transfection, Immunoprecipitaion, and Electrophoretic Mobility As-
says.
 
293 cell transfection, coimmunoprecipititaion, and West-
ern blot analysis were performed as described (4). For JNK kinase
assay, cell lysates were first immunoprecipitated with anti-JNK
monoclonal antibody (BD PharMingen). The kinase activity was
then determined by using 2 
 
m
 
g of glutathione 
 
S
 
-transferase
(GST)-JUN (Stratagene). Electrophoretic mobility assays were
performed as described (18). 
 
Results and Discussion
 
Using FACS
 
®
 
 analysis with an Fc-tagged TALL-1 pro-
tein, we found that the human Burkitt’s lymphoma RAJI
cell line expresses a high level of TALL-1 receptor. A plas-
mid cDNA expression library was constructed from RAJI
mRNA and arrayed in pools of 100 clones. Individual
pools were transfected into 293 cells and assayed for the ac-
quisition of Europium-labeled TALL-1 recombinant pro-
tein. Out of 3,000 pools, we were able to identify and con-
firm 6 primary positive pools. The positive binding signals
from these six primary pools ranged from a 2–10-fold in-
crease compared with the rest of the pools (data not 
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shown). Positive pools 13B4 and 13H11 were then subdi-
vided. Both clones encoded full-length TACI, a previously
reported TNFR family member identified through its in-
teraction with CAML (17). The single positive clone re-
covered from pool 13H4 has an extra 7 bp in the 5
 
9
 
 un-
translated region of the cDNA insert, compared with the
positive clone isolated from pool 13B4. By PCR analysis,
the rest of the four primary positive pools also contained
full-length TACI DNA sequence, which likely contributed
to the TALL-1 binding activities. The interaction of TACI
with TALL-1 was further confirmed by FACS
 
®
 
 analysis.
293 T cells were transfected with control vector or TACI
expression vector. Transfected cells were then stained with
Fc-tagged TALL-1 protein followed by FITC-conjugated
secondary antibody. TALL-1 bound only to TACI-trans-
fected 293 cells, but not vector-transfected cells (Fig. 1 B).
A20, a mouse B lymphoma cell line, exhibited high
TALL-1 binding activity as determined by FACS
 
®
 
 analysis
with Fc-tagged TALL-1 (data not shown). The mouse
TACI cDNA was subsequently isolated from A20 cDNA
library using human TACI cDNA as a probe. The mouse
TACI gene encodes a protein of 249 amino acids, lacking
30 amino acids at the NH
 
2
 
 terminus compared with the
human TACI (Fig. 1 A).   Human and mouse TACI share
54% identity overall. Six cysteines within the cysteine-rich
repeats in the extracellular domain are spatially conserved
in both species. Of note, the intracellular domains of hu-
man and murine TACI are poorly conserved except for a
region of 20 amino acids (Fig. 1 A). The interaction be-
tween TALL-1 and mouse TACI was confirmed by 293
cell transfection with mouse TACI and subsequent FACS
 
®
 
analysis with Fc-tagged TALL-1 protein (Fig. 1 B).
Previous studies by von Bulow and Bram (17) showed
expression of TACI on B cells and activated T cells. The B
cell expression of TACI correlates with TALL-1 B cell
binding and stimulatory activities (11, 13, 14). We used
PBMCs from healthy donors to determine if TALL-1 also
binds activated T cells. As shown in Fig. 2, T cells express
Figure 1.  TACI is the cell surface receptor for TALL-1. (A) Compar-
ison of human and murine TACI. The amino acid sequences of human
and murine TACI are aligned. Transmembrane regions are underlined.
(B) FACS® analysis of TALL-1 binding to TACI-transfected 293 cells.
293 cells (3 3 105) were transiently transfected with vector, human
TACI, or murine TACI expression vector. After 24 h, cells were first ex-
posed to 1 mg/ml Fc-tagged TALL-1 protein, then stained with FITC-
conjugated goat F(ab9)2 anti–human IgG.
Figure 2.  Expression of TALL-1 receptor on activated CD4- and
CD8-positive T cells.   PBMCs from healthy donors were activated using
anti-CD3 antibody (1 mg/ml) for the indicated period of time, and cell
surface receptors for TALL-1 were examined by flow cytometry using
Flag-tagged TALL-1, anti-Flag biotin antibody, and streptavidin-PE re-
agents (red histogram). Anti-Flag biotin antibody and streptavidin-PE re-
agents were used as control for each set of experiments (black histogram).
CD4- or CD8-positive T cells were gated to analyze expression of
TALL-1 receptor on specific cell types. FL2-H represents log fluores-
cence intensity. 
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very low levels of TALL-1 receptors. Upon activation with
anti-CD3 antibody, an increase in TALL-1 staining was
found in both CD4 and CD8 T cells. The expression of
TALL-1 receptors was higher on activated CD4 cells com-
pared with CD8 T cells at all of the time points studied af-
ter activation. The biological role of TACI on activated T
cells remains to be determined. In conclusion, the TALL-1
binding specificity correlates with TACI expression profile,
supporting the fact that TACI is a receptor for TALL-1.
Soluble human TACI recombinant protein (amino acids
1–165) fused with a COOH-terminal His-tag was gener-
ated in 
 
E. coli
 
. Gel filtration analysis indicated that the solu-
ble receptor has a molecular mass of 24 kD, the size of a
monomer. The binding kinetics of TALL-1 and TACI
were examined by BIAcore analysis. Human and murine
TALL-1 bind to human TACI with an affinity of 0.2 nM
and 0.3 nM, respectively. Unlike other TNFR family
members, both human and murine TACI have an extra-
long stalk region of 
 
z
 
60 amino acids following the cysteine
repeats at the extracellular domains. This stalk region is not
required for the ligand-binding activity. When deleted, the
remaining cysteine-rich repeat region (amino acids 1–105)
retained TALL-1 binding activity (data not shown).
We recently reported that TALL-1 is a potent B cell co-
stimulatory factor with an ED
 
50
 
 of 
 
z
 
3 ng/ml. TALL-1–
mediated B cell proliferation was completely blocked by
soluble TACI extracellular domain protein (Fig. 3). This
inhibitory effect was very potent. In the presence of an
equal molar ratio of TALL-1 and TACI, B cell prolifera-
tion mediated through TALL-1 was inhibited by 50%. This
inhibitory effect by soluble TACI protein was not observed
when B cell proliferation was induced by anti-CD40 anti-
body or LPS (Fig. 3). The specific inhibition of TALL-1–
mediated B cell proliferation by soluble TACI protein
strongly suggests that TACI serves as a physiological cell
surface receptor for TALL-1.
We next examined the effect of soluble TACI protein
treatment on the production of anti-KLH and anti-Pneu-
movax antibodies in mice. It is well known that IgG pro-
duction in response to KLH requires T cell help, whereas
anti-Pneumovax IgM production is T cell independent
(19). Treatment with soluble TACI protein fused with Fc
Figure 3. Soluble TACI protein specifically inhibited TALL-1–medi-
ated B cell proliferation. Purified B cells (105) from B6 mice were cul-
tured in triplicates in 96-well plates with the indicated amounts of soluble
TACI extracellular domain protein in the presence of 10 ng/ml TALL-1
plus 2 mg/ml anti-IgM antibody (top), 1 mg/ml anti-CD40 antibody plus
2 mg/ml anti-IgM antibody (middle), or 0.5 mg/ml LPS (bottom) for a
period of 4 d. Proliferation was measured by radioactive [3H]thymidine
uptake in the last 18 h of pulse. Data shown represent mean 6 SD of
triplicate wells.
Figure 4. Soluble  TACI-Fc
fusion protein inhibits anti-KLH
and anti-Pneumovax antibody
production. Mice (n 5 7) were
treated with 5 mg/kg TACI-Fc
fusion protein or nonfused Fc
protein each day for 7 d. Serum
levels of anti-KLH IgG and IgM
and anti-Pneumovax were mea-
sured on day 7 by ELISA. 
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significantly inhibited the production of anti-KLH and
anti-Pneumovax antibodies. Serum levels of anti-KLH IgG
and IgM were reduced approximately four- and fivefold,
respectively, in the soluble TACI-Fc treated mice com-
pared with the control group (Fig. 4). Serum levels of anti-
Pneumovax IgM were also about four times lower in the
soluble TACI-Fc treated mice than in controls (Fig. 4).
These findings suggest that the TALL-1–TACI interaction
is involved in the generation of both T cell–dependent and
independent humoral responses.
To identify signaling molecules that TACI uses during B
cell stimulation, the intracellular domain of TACI was used
as bait in the yeast two-hybrid screening of human B cell
library. From 8 
 
3 
 
10
 
6
 
 transformants, 48 positive clones
were recovered. The majority of the positive clones en-
coded TRAF2. In addition to TRAF2, TACI intracellular
domain also interacted with TRAF5 and TRAF6. The
TRAF-binding sites were mapped by deletion mutagenesis
in a yeast two-hybrid interaction assay (Fig. 5 A). Both
TRAF2- and TRAF5-binding sites colocalized within
amino acid residues 231–253 of the human TACI intracel-
lular domain. The TRAF6-binding site occupies an over-
lapping but broader region from amino acid residues 220–
253. It remains to be determined if the TRAF6-binding
site is physically separated from the TRAF2- and TRAF5-
binding sites within this small region. Interestingly, these
TRAF binding sites are the only well-conserved regions
between human and murine TACI intracellular domain se-
quences (Fig. 1 A). 
TACI was initially reported as a CAML-binding protein
isolated using CAML fused with the GAL4 DNA-binding
domain as bait in a yeast two-hybrid screening. In our two-
hybrid screening of B cell library with TACI intracellular
domain, we did not retrieve CAML among the positive
binding clones. However, as reported, we were also able to
detect coimmunoprecipitation of TACI with myc-tagged
CAML from transfected 293 cells (Fig. 5 B). Correspond-
ing to the yeast interaction, TACI was also coimmunopre-
cipitated with myc-tagged TRAF2, 5, and 6.   Incubation
of the same transfected lysates with mouse IgG did not co-
precipitate TACI proteins (data not shown). Deletion of 60
amino acids from the TACI COOH terminus abolished its
interaction with TRAF2, 5, and 6, consistent with the
yeast deletion mapping results (Fig. 5 B). Interestingly, the
Figure 5. TACI interacts with
TRAF proteins and induces NF-
kB and JNK activation. (A)
Mapping of TACI TRAF-bind-
ing domains. Expression vectors
encoding full-length or deletion
mutants of TACI intracellular
domain fused to the GAL4
DNA–binding domain were
cotransformed into the HF7C
yeast strain with vectors express-
ing the GAL4 activation fused
with TRAF2, 5, and 6. Plus
signs represent growth after 1 wk
on the selection plates. (B)
Coimmunoprecipitation of
TACI with TRAF and CAML
proteins. 293 cells (3 3 105)
were cotransfected with expres-
sion vectors directing synthesis of
NH2-terminal Flag-tagged wild-
type (wt) TACI or TACI dele-
tion mutants along with myc-
tagged CAML, TRAF2,
TRAF5, and TRAF6 expres-
sion vectors. After 24 h, cell ly-
sates were immunoprecipitated
with monoclonal antibody
against myc epitope. Coprecipi-
tated Flag-tagged TACI mutants,
as indicated by arrows, were de-
tected by immunoblot analysis
with anti-Flag monoclonal anti-
body. For each transfection sam-
ple, TACI wild-type or mutants
were not detected when mouse
IgG was used for the immuno-
precipitation (data not shown).
(C) NF-kB activation induced by TALL-1. Approximately 107 A20 cells were left untreated or were treated with 100 ng/ml TALL-1 for 2 h. Nuclear
extracts were prepared, incubated with the 32P-labeled NF-kB oligonucleotide probe, and subjected to electrophoretic mobility shift analysis. (D) JNK
activation induced by TALL-1. Approximately 106 A20 cells were exposed to 100 ng/ml TALL-1 for the indicated length of time. The cell lysates were
immunoprecipitated with monoclonal anti-JNK antibody. Immunoprecipitates were assayed for kinase activity by using GST-JUN as substrate.142 TALL-1 Receptor TACI Interacts with TRAF Proteins
same deletion mutant TACI (1–233) still retained CAML-
binding activity, suggesting that the TRAF-binding and
CAML-binding sites of TACI reside in two separable re-
gions (Fig. 5 B). The TRAF2, 5, and 6 knockout mice will
be useful tools to evaluate the biological roles of these
TRAF proteins in TALL-1 signaling pathways.
Most TRAF-binding TNFR family members, upon ac-
tivation by their ligands, induce NF-kB and JNK activa-
tion. These two potential signaling events were evaluated
in TALL-1–treated A20 cells, which express TACI. NF-
kB activation was readily detected from A20 cell nuclear
extracts after exposure to TALL-1 for 2 h, as determined
by electrophoretic mobility assays with NF-kB oligos (Fig.
5 C). To detect JNK activation, A20 cells were induced
with TALL-1 for the indicated periods of time. Activation
of JNK was readily detectable after 5 min of TALL-1 treat-
ment, and rapidly decreased after 30 min of exposure (Fig.
5 D). Hence, like many other TRAF-binding TNFR fam-
ily members, TALL-1 induces NF-kB and JNK activation
upon binding to its cell surface receptor TACI, which may
then contribute to B cell survival and proliferation.
Our findings clearly demonstrate that TACI is a signaling
receptor for TALL-1. This observation was recently re-
ported by Gross et al. (20) during the preparation of this
manuscript. In addition to TACI, Gross et al. also demon-
strated that B cell maturation antigen (BCMA) is another
receptor for TALL-1. We also noted TALL-1 binding to
BCMA-transfected 2939 cells (Fig. 6 A). Of note, in
TALL-1–responsive A20 cells, BCMA expression was not
detectable by Northern blot analysis, whereas TACI ex-
pression is high (Fig. 6 B). TACI mRNA was readily de-
tected in RAJI cells, spleen, and other organs rich in lym-
phoid tissues (Fig. 6 B). In comparison, after the same
period of exposure, BCMA expression was weakly de-
tected in RAJI cells, and was not detectable in the other
tissues examined (Fig. 6 B). After longer exposure, BCMA
mRNA was detected in the small intestine and spleen (data
not shown). The observation of the different expression
levels of the two receptors may provide some insight into
their respective biological roles. However, the generation
of specific neutralizing antibodies or knockout mice will
provide more useful information in this regard. TALL-1
has been implicated in B cell–mediated autoimmune dis-
eases such as SLE (11,16, and 20). The identification and
functional study of TALL-1 receptors provide an advance-
ment in our understanding of B cell survival and prolifera-
tion, and represent a clear step forward in the development
of potential treatment for these diseases.
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